journal article·2024-07Open access

Multifunctional Fluoropolymer‐Engineered Magnetic Nanoparticles to Facilitate Blood‐Brain Barrier Penetration and Effective Gene Silencing in Medulloblastoma

Helen Forgham, Jiayuan Zhu, Xumin Huang, Cheng Zhang, Heather Biggs, Liwei Liu, Yi Cheng Wang, Nicholas Fletcher, James Humphries, Gary Cowin, Karine Mardon, Maria Kavallaris, Kristofer Thurecht, Thomas P. Davis, Ruirui Qiao

Advanced Science· Volume 11· Issue 25

Abstract

Abstract Patients with brain cancers including medulloblastoma lack treatments that are effective long‐term and without side effects. In this study, a multifunctional fluoropolymer‐engineered iron oxide nanoparticle gene‐therapeutic platform is presented to overcome these challenges. The fluoropolymers are designed and synthesized to incorporate various properties including robust anchoring moieties for efficient surface coating, cationic components to facilitate short interference RNA (siRNA) binding, and a fluorinated tail to ensure stability in serum. The blood‐brain barrier (BBB) tailored system demonstrates enhanced BBB penetration, facilitates delivery of functionally active siRNA to medulloblastoma cells, and delivers a significant, almost complete block in protein expression within an in vitro extracellular acidic environment (pH 6.7) – as favored by most cancer cells. In vivo, it effectively crosses an intact BBB, provides contrast for magnetic resonance imaging (MRI), and delivers siRNA capable of slowing tumor growth without causing signs of toxicity – meaning it possesses a safe theranostic function. The pioneering methodology applied shows significant promise in the advancement of brain and tumor microenvironment‐focused MRI‐siRNA theranostics for the better treatment and diagnosis of medulloblastoma.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Australian Institute of Bioengineering & Nanotechnology The University of Queensland St Lucia Queensland 4072 Australia

National Imaging Facility Centre for Advanced Imaging The University of Queensland St Lucia Queensland 4072 Australia

ARC Training Centre for Innovation in Biomedical Imaging Technology The University of Queensland St Lucia Queensland 4072 Australia

Children's Cancer Institute Lowy Cancer Research Centre UNSW Sydney Kensington New South Wales 2052 Australia

School of Clinical Medicine Faculty of Medicine & Health UNSW Sydney Kensington New South Wales 2052 Australia

UNSW Australian Centre for Nanomedicine Faculty of Engineering UNSW Sydney Kensington New South Wales 2052 Australia

UNSW RNA Institute Faculty of Science UNSW Sydney Kensington New South Wales 2052 Australia

Funding

National Health and Medical Research Council

References (85)

Show source-provided references
1. 10.1007/s11910-023-01316-910.1007/s11910-023-01316-9 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. 10.1093/nop/npw01310.1093/nop/npw013 ↗
4. 10.3762/bjnano.11.7210.3762/bjnano.11.72 ↗
5. 10.3389/fnagi.2019.0037310.3389/fnagi.2019.00373 ↗
6. 10.1002/EXP.2022001210.1002/EXP.20220012 ↗
7. 10.1021/acsapm.2c0129110.1021/acsapm.2c01291 ↗
8. 10.1016/j.lfs.2021.11936810.1016/j.lfs.2021.119368 ↗
9. 10.1126/sciadv.abf739010.1126/sciadv.abf7390 ↗
10. 10.3390/jpm1108077110.3390/jpm11080771 ↗
11. 10.3389/fcell.2022.82429910.3389/fcell.2022.824299 ↗
12. 10.1021/acs.biomac.9b0115810.1021/acs.biomac.9b01158 ↗
13. 10.1021/acsanm.1c0413810.1021/acsanm.1c04138 ↗
14. 10.1039/C7BM01012E10.1039/C7BM01012E ↗
15. 10.1016/j.biomaterials.2016.10.01110.1016/j.biomaterials.2016.10.011 ↗
16. 10.1021/mp900143a10.1021/mp900143a ↗
17. 10.1021/jp802507210.1021/jp8025072 ↗
18. 10.1016/j.biomaterials.2017.02.03710.1016/j.biomaterials.2017.02.037 ↗
19. 10.1002/advs.20200040610.1002/advs.202000406 ↗
20. 10.1021/acs.biomac.0c0119310.1021/acs.biomac.0c01193 ↗
21. 10.1002/adma.20130474410.1002/adma.201304744 ↗
22. 10.1007/s12274-020-2839-010.1007/s12274-020-2839-0 ↗
23. 10.1002/advs.20200040610.1002/advs.202000406 ↗
24. 10.1002/anie.20191411910.1002/anie.201914119 ↗
25. 10.1039/C6TB01929C10.1039/C6TB01929C ↗
26. 10.1021/acsapm.8b0010510.1021/acsapm.8b00105 ↗
27. 10.1016/j.msec.2016.04.05710.1016/j.msec.2016.04.057 ↗
28. 10.1021/acs.macromol.1c0218610.1021/acs.macromol.1c02186 ↗
29. 10.1021/acs.chemrev.1c0063210.1021/acs.chemrev.1c00632 ↗
30. 10.1021/acs.chemmater.9b0384110.1021/acs.chemmater.9b03841 ↗
31. 10.1016/B978-0-323-39500-7.00001-010.1016/B978-0-323-39500-7.00001-0 ↗
32. 10.1016/j.addr.2019.05.00410.1016/j.addr.2019.05.004 ↗
33. 10.1021/ja203340u10.1021/ja203340u ↗
34. 10.1038/nmat125110.1038/nmat1251 ↗
35. 10.1016/j.msec.2014.07.02910.1016/j.msec.2014.07.029 ↗
36. 10.2147/IJN.S30413810.2147/IJN.S304138 ↗
37. 10.1021/acs.biomac.8b0128210.1021/acs.biomac.8b01282 ↗
38. 10.1021/acsanm.8b0228310.1021/acsanm.8b02283 ↗
39. 10.1021/acsami.8b1559410.1021/acsami.8b15594 ↗
40. 10.1002/smll.20110186310.1002/smll.201101863 ↗
41. 10.2217/nnm-2017-002210.2217/nnm-2017-0022 ↗
42. 10.1038/s41598-020-75253-910.1038/s41598-020-75253-9 ↗
43. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
44. 10.18632/oncotarget.266410.18632/oncotarget.2664 ↗
45. 10.1021/nn102540y10.1021/nn102540y ↗
46. 10.1016/j.biomaterials.2022.12153910.1016/j.biomaterials.2022.121539 ↗
47. 10.1016/j.jfda.2014.01.00510.1016/j.jfda.2014.01.005 ↗
48. 10.1186/1471-2407-12-8010.1186/1471-2407-12-80 ↗
49. 10.1093/neuonc/noab20710.1093/neuonc/noab207 ↗
50. 10.1073/pnas.160824711310.1073/pnas.1608247113 ↗
51. 10.2967/jnumed.109.06898110.2967/jnumed.109.068981 ↗
52. 10.1038/s41467-018-05261-x10.1038/s41467-018-05261-x ↗
53. 10.1158/1538-7445.AM2023-156110.1158/1538-7445.AM2023-1561 ↗
54. 10.1371/journal.pone.011106010.1371/journal.pone.0111060 ↗
55. 10.1128/MCB.26.6.2093-2108.200610.1128/MCB.26.6.2093-2108.2006 ↗
56. 10.1038/sj.onc.120821810.1038/sj.onc.1208218 ↗
57. 10.1002/smll.20210497710.1002/smll.202104977 ↗
58. 10.1002/adma.20230128310.1002/adma.202301283 ↗
59. 10.1021/acsnano.2c0591710.1021/acsnano.2c05917 ↗
60. 10.1007/s00330010090810.1007/s003300100908 ↗
61. 10.1016/j.celrep.2021.10901310.1016/j.celrep.2021.109013 ↗
62. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
63. 10.1002/adma.20230409810.1002/adma.202304098 ↗
64. 10.1021/acs.accounts.1c0076610.1021/acs.accounts.1c00766 ↗
65. 10.1021/acsnano.8b0372610.1021/acsnano.8b03726 ↗
66. 10.1021/acsnano.0c0295410.1021/acsnano.0c02954 ↗
67. 10.1038/nrc311010.1038/nrc3110 ↗
68. 10.1038/s41467-018-05261-x10.1038/s41467-018-05261-x ↗
69. 10.3389/fbioe.2023.119923010.3389/fbioe.2023.1199230 ↗
70. 10.1021/acsnano.7b0542810.1021/acsnano.7b05428 ↗
71. 10.1039/D1TB01473K10.1039/D1TB01473K ↗
72. 10.1007/s00775-020-01800-410.1007/s00775-020-01800-4 ↗
73. 10.1016/j.nano.2018.04.00210.1016/j.nano.2018.04.002 ↗
74. 10.1021/acsami.9b0354210.1021/acsami.9b03542 ↗
75. 10.7150/thno.3097710.7150/thno.30977 ↗
76. 10.1038/s41467-020-15818-410.1038/s41467-020-15818-4 ↗
77. 10.1002/mrm.2295910.1002/mrm.22959 ↗
78. 10.4155/fsoa-2017-005410.4155/fsoa-2017-0054 ↗
79. 10.1088/2053-1591/aa96e310.1088/2053-1591/aa96e3 ↗
80. 10.1002/anie.20221307110.1002/anie.202213071 ↗
81. 10.1038/nprot.2007.24910.1038/nprot.2007.249 ↗
82. 10.1021/mp400049e10.1021/mp400049e ↗
83. 10.1016/j.ijpharm.2018.09.04010.1016/j.ijpharm.2018.09.040 ↗
84. 10.1021/jacs.8b0937410.1021/jacs.8b09374 ↗
85. 10.1021/acs.molpharmaceut.2c0076010.1021/acs.molpharmaceut.2c00760 ↗